Company profile
AGIOS PHARMACEUTICALS, INC.
NASDAQ:AGIOBiotechnology: Pharmaceutical Preparations
Drug pipeline (4)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| IVOSIDENIB | phase1_2 | — | 2 | active |
| Mitapivat | phase3 | — | 8 | active |
| Mitapivat sulfate | approved | — | 1 | approved |
| Vorasidenib | phase1 | — | 2 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (46)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06924970 | phase2 | active_not_recruiting | 2025-05-01 | 2026-05-12 | Agios Pharmaceuticals, Inc. | A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD) |
| NCT05610657 | phase1 | completed | 2023-01-10 | 2023-07-21 | Agios Pharmaceuticals, Inc. | A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function |
| NCT02108106 | phase1 | completed | 2014-03-01 | 2014-08-01 | Agios Pharmaceuticals, Inc. | A Phase I Study of AG-348 in Healthy Volunteers |
| NCT02149966 | phase1 | completed | 2014-05-01 | 2014-11-01 | Agios Pharmaceuticals, Inc. | A Phase I Study of AG-348 in Healthy Volunteers |
| NCT03960502 | phase1 | completed | 2019-05-16 | 2019-09-07 | Agios Pharmaceuticals, Inc. | A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881 |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 216196 | NDA | AGIOS PHARMACEUTICALS INC | ||||
Loading… | ||||||